GU Cancers 2022 | OS after progression on first novel hormonal therapy in mCSPC vs mCRPC

Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, details the results of a retrospective study evaluating overall survival (OS) of novel hormonal therapies in patients who progressed on first-line hormonal therapy and whether there is a difference between patients with metastatic castration-sensitive (mCSPC) versus castration-resistant prostate cancer (mCRPC). These results suggest median OS is similar after progression on hormonal therapy whether given in the first-line mCSPC or first-line mCRPC setting. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.